Last reviewed: June 21, 2026
Last updated: June 21, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide works by signaling your brain that you're satisfied after smaller meals, reducing hunger hormones and slowing stomach emptying. Clinical trials show most patients experience appetite suppression within the first week, but visible weight loss typically emerges between weeks 4 and 6. Understanding this timeline helps you stay motivated and manage realistic expectations as your body adapts.
When Does Semaglutide Start Working on Appetite?
The appetite-suppressing effects of semaglutide begin almost immediately—many patients report feeling fuller faster within 3–7 days of their first injection. This happens because semaglutide activates GLP-1 receptors in the brain's appetite control centers, signaling satiety before you've eaten as much as usual. You may notice you naturally eat smaller portions at meals or skip snacks you normally crave.
Early appetite changes don't always translate to rapid weight loss on the scale, however. During the first 2–3 weeks, your body is still adjusting to lower food intake, and water retention or inflammation shifts can mask fat loss. This is completely normal and does not indicate the medication isn't working—it simply means your metabolic adaptation is in progress.
Weight Loss Timeline: First 4–6 Weeks
Between weeks 4 and 6, most people on semaglutide see their first meaningful scale movement, typically ranging from 2–5 pounds. This initial loss reflects a combination of reduced calorie intake (from smaller meals and fewer cravings), glycogen depletion, and early fat mobilization. Your dose during this window is usually still in the lower range (0.25–0.5 mg weekly), so more significant weight loss typically accelerates as your dose increases over subsequent months.
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), and FTO (rs9939609) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Months 2–3: When Weight Loss Accelerates
As your semaglutide dose escalates toward the therapeutic range (1.0–2.4 mg weekly), weight loss typically accelerates during months 2 and 3. Many patients lose 5–10 pounds per month during this window, especially if combined with modest dietary consistency and movement. The appetite suppression becomes more robust, and your body has fully adapted to lower calorie intake without the intense hunger that typically accompanies restriction.
This acceleration phase is also when you may notice non-scale victories: clothes fitting better, improved energy levels, better blood sugar control, and reduced joint stress. Some people experience a plateau around week 8–10, which is temporary and normal. Your prescriber may adjust your dose or PlexusDx may recommend reviewing your Precision Peptide results to identify any peptide-pathway adjustments that could optimize your response.
Long-Term Results and Sustained Weight Loss
Clinical trials of semaglutide show sustained weight loss over 52+ weeks, with average reductions of 10–15% of starting body weight at therapeutic doses. Crucially, weight loss continues to progress beyond the first three months for most people, reaching a personal plateau around months 6–12 depending on starting weight and lifestyle factors. The medication works continuously as long as you maintain it—stopping semaglutide typically leads to weight regain within months.
PlexusDx Semaglutide Injection starts at $189/mo (or $149/mo on the 6-month plan) with no flat per-compound pricing escalation, meaning your dose may need to go up but your price won't. This flat-rate model removes financial barriers to reaching your therapeutic dose. Long-term success depends on consistent treatment, regular monitoring, and lifestyle support—factors that PlexusDx coordinates through its personalized therapy model and optional Precision Peptide Genetic Test guidance.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I see weight loss results in the first week of semaglutide?
No, visible scale weight loss typically takes 3–4 weeks to appear. However, appetite suppression and reduced food intake start within days. Early changes on the scale (if any) are usually water loss rather than fat loss. Patience through this adjustment period is key to long-term success.
What if I'm not losing weight after 6 weeks?
If you're not seeing any scale movement by week 6, discuss with your prescriber whether your dose is sufficient, your dietary adherence is consistent, or if underlying metabolic factors need investigation. PlexusDx recommends the Precision Peptide Genetic Test after your first month to identify genetic variants affecting peptide-pathway sensitivity—this can guide dose optimization and realistic timelines specific to your biology.
How much weight can I expect to lose per month on semaglutide?
Average loss is 2–5 pounds in weeks 4–6, then 5–10 pounds per month during months 2–3 as your dose reaches therapeutic levels. Beyond three months, loss typically slows to 1–3 pounds per month as you approach your body's set point. Individual results vary based on starting weight, metabolism, and adherence.
What happens if I stop semaglutide?
Weight regain typically begins within weeks of stopping semaglutide, as appetite hormones return to baseline and hunger increases. Most people regain 50% of lost weight within one year off the medication. Semaglutide is designed for long-term use, and PlexusDx supports continuous treatment at $189/month to prevent costly cycles of loss and regain.
How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?
Yes. PlexusDx's Precision Peptide Genetic Test analyzes 14 pathways across 49 peptides, including GLP1R variants that directly influence how your body responds to semaglutide. Variants like GLP1R rs6923761 and GIPR rs1800437 can indicate whether you'll be a rapid responder or need more gradual dose escalation, helping set realistic monthly weight loss expectations.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Should You Eat Before Your Zepbound Shot? Understanding the Best Practices
Ozempic® and GERD: Navigating Your Weight Loss Journey with Personalized Care